High Prevalence of Cutaneous Human Papillomavirus DNA on the Top of Skin Tumors but not in “Stripped” Biopsies from the Same Tumors  by Forslund, Ola et al.
See related Commentaries on pages iv, vi and xi
High Prevalence of Cutaneous Human Papillomavirus DNA on
the Top of Skin Tumors but not in ‘‘Stripped’’ Biopsies from
the Same Tumors
Ola Forslund, Bernt Lindelo¨f,w Eva Hradil,z Peter Nordin,y Bo Stenquist,z Reinhard Kirnbauer,#
Katharina Slupetzky,# and Joakim Dillner
Department of Medical Microbiology, Malmo¨ University Hospital, Lund University, Malmo¨, Sweden; wDepartment of Dermatology, Karolinska Hospital,
Stockholm, Sweden; zDepartment of Dermatology, Malmo¨ University Hospital, Malmo¨, Sweden; yDermatology Clinic La¨karhuset Gothenburg, Sweden;
zDepartment of Dermatology, Sahlgrenska University Hospital, Gothenburg, Sweden; #Department of Dermatology, Allergy and Infectious Diseases (DAID),
University of Vienna Medical School, Vienna, Austria
Genomes of human papillomaviruses (HPV) are common in biopsies from non-melanoma skin cancers but are also
found on healthy skin and it is possible that HPV positivity in tumor biopsies by PCR may merely reﬂect
contamination of the lesion surface. To investigate this issue, 229 immunocompetent patients were tested for HPV
DNA in swab samples collected on top of skin tumors and in biopsies of the same tumors, obtained after stripping
with tape to remove superﬁcial layers. HPV DNA was detected on top of 69% (159 of 229) of the lesions, and in 12%
(28 of 229) of the stripped biopsies (po0.001). The difference was seen for all four types of tumors studied.
Seborrheic keratosis had 79% (34 of 43) HPV positivity on top of lesions versus 19% (eight of 43) in biopsies; actinic
keratosis had 83% (38 of 46) HPV positivity on top versus 11% (ﬁve of 46) in biopsies; basal cell carcinoma had 63%
(69 of 109) on top versus 8% (nine of 109) in biopsies and squamous cell carcinoma had 58% (18 of 31) on top versus
19% (six of 31) in biopsies. HPV DNA is common in superﬁcial layers of lesions, but is not necessarily present
throughout tumors.
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Certain types of human papillomaviruses (HPV) have the
potential to induce malignant and benign genital tumors
(Burd, 2003). The HPV types from supergroup B (HPV 5 and
related HPV types originally isolated from Epidermodyspla-
sia verruciformis) have cutaneous tropism but their possible
role in the etiology of non-melanoma skin cancers is not
clear. The DNA of cutaneous HPV types is found both in
pre-malignant lesions and non-melanoma skin cancers,
especially among immunosuppressed organ transplant
patients (Pfister and Ter Schegget, 1997; Kiviat, 1999;
Bouwes Bavinck et al, 2001). Renal transplant patients have
up to about 100-fold increased risk to develop cutaneous
squamous cell carcinoma (SCC) (Lindelof et al, 2000), and
the cumulative incidence of non-melanoma skin cancer 20 y
after transplantation is as much as 70% in Australia
(Bouwes Bavinck et al, 1996) and 40% in The Netherlands
(Hartevelt et al, 1990).
Several possible mechanisms of how HPV might act
as cofactors in cutaneous cell transformation have been
proposed. The promoter activity of HPV type 77 is
stimulated by ultraviolet radiation and the response is
mediated through a binding site for the p53 tumor
suppressor protein in the upper regulatory region of the
virus (Purdie et al, 1999). Moreover, ultraviolet-induced
cytokines and interferons have been found to activate the
promoter of the cutaneous HPV type 20 (Ruhland and de
Villiers, 2001). The E6 proteins of cutaneous HPV types
seem to harbor relatively low oncogenic capability, showing
transformation and anchorage-independent growth of ro-
dent cells, but without forming tumors in nude mice (Iftner
et al, 1988; Kiyono et al, 1989). Recently, primary human
cells were reported to be transformed by E6 of HPV 38
(Caldeira et al, 2003); however, the E6 protein of the
cutaneous HPV types appear to be unable to promote
degradation of p53 (Steger and Pfister, 1992; Jackson et al,
2000), in contrast to that of oncogenic genital HPV types
(Tommasino et al, 2003).
The E6 protein of cutaneous human papillomaviruses
might promote genomic instability of infected cells since it
was demonstrated that E6 of HPV types 1 and 8 (and HPV
type 16) binds to the XRCC1 protein (required for the repair
of DNA single-strand breaks and genetic stability) (Iftner
et al, 2002). Also, the E6 protein of cutaneous HPV 5, 10,
and 77 binds the pro-apoptotic Bak protein (Jackson and
Storey, 2000). This could inhibit Bak-induced apoptosis
following ultraviolet radiation that could result in accumula-
tion of deleterious mutational changes. Mutations are
Abbreviations: AK, actinic keratosis; BCC, basal cell carcinomas;
HPV, human papillomavirus; SCC, squamous cell carcinoma; SK,
seborrheic keratosis
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frequent in SCC of the skin and more than 90% of such
lesions demonstrate mutations in the tumor suppressor
gene p53 (Leffell, 2000).
So far, the vast majority of studies to detect cutaneous
HPV DNA have used sensitive PCR methods, whereas less
sensitive methods such as Southern blot are only infre-
quently able to detect HPV in skin lesions (Kawashima et al,
1990), indicating very low amounts of viral genomes (Bens
et al, 1998; Meyer et al, 2001). But common skin warts
appear to have higher amounts of viral genomes, since HPV
DNA (predominantly HPV 1 and 2) is readily detectable by
the Southern blot technique (Corley et al, 1988).
A significant problem for investigations of an association
between cutaneous HPV and non-melanoma skin cancer is
that cutaneous HPV is part of the microbiological flora of
healthy human skin (Boxman et al, 1997; Astori et al, 1998;
Antonsson et al, 2000, 2003a, b; Wieland et al, 2000;
Forslund et al, 2003). The site for replication of cutaneous
HPV DNA might be stem cells of the hair follicle (Schmitt
et al, 1996; Boxman et al, 1997, 2000b) or of eccrine ducts
(Egawa, 2003). These sites could also be the origin for non-
melanoma skin cancer (Egawa, 2003; Perez-Losada and
Balmain, 2003); however, it is not known whether cutaneous
HPV are involved in the development of skin cancers.
Neither is it known if findings of HPV DNA from healthy skin
represent viral particles or superficial cells containing
episomal HPV genomes.
If viral particles are produced and shed from infected
healthy skin, they are likely to be contaminating large areas
of the body surface, including the surface of skin tumors. If
so, punch biopsies of tumors might be scored as HPV
positive by PCR, although the viral DNA is not present
throughout the tumor. To address this question, we
investigated whether the HPV DNA prevalence on top of
skin lesions was similar to that in stripped biopsies from the
same tumors.
Results
Quality control In the DNA quality/quantity test, the
biopsies and the swab samples from the lesions were
found positive for the b-globin gene in 100% (229 of 229)
and 89% (203 of 229), respectively. The b-globin negative
swab samples were found among seborrheic keratosis (SK)
in 37% (16 of 43), actinic keratosis (AK) in 6% (three of 46),
and basal cell carcinomas (BCC) in 6% (seven of 109). The
proportions of HPV DNA positivity among these b-globin
negative samples were 69% (11 of 16) for SK, 66% (two of
three) for AK, and 28% (two of seven) for BCC.
Prevalence of HPV DNA HPV DNA was detected in 69%
(159 of 229) of the swab samples collected on the top of the
lesions, whereas a significantly lower HPV DNA prevalence
of 12% (28 of 229) was detected in the stripped biopsies
of the same lesions (po0.001). Specifically, HPV DNA was
detected in 79% (34 of 43) of the swab samples vs 19%
(eight of 43) in the stripped biopsies of SK, 83% (38 of 46)
vs 11% (five of 46) of AK, 63% (69 of 109) vs 8% (nine of
109) of BCC, and 58% (18 of 31) vs 19% (six of 31) of SCC
(Table I).
Swab samples from the top of the lesions with benign
diagnoses as AK and SK showed significantly higher HPV
DNA prevalences than that in swab samples of malignant
lesions (SCC and BCC) (AK vs SCC, p¼ 0.02; AK vs BCC,
p¼0.01; SK vs SCC, p¼0.04; SK vs BCC, p¼0.04).
Among swab samples containing large amounts of ampli-
cons (band intensity Xþ þ þ ), AK had the highest HPV
DNA prevalence of 41% (19 of 46), significantly higher than
13% (four of 31) found in SCC (po0.010) (Table I).
There was at least one common HPV type detected in
52% (13 of 25) of HPV-positive pairs of stripped biopsies
and superficial lesional swabs (Table S1).
For swab samples collected at other sites, HPV DNA
prevalences between 73% and 84% were observed, which
decreased to between 32% and 46% for samples contain-
ing large amounts of amplicons (Xþ þ þ ) (Table I).
HPV sequences Among the 28 HPV-positive biopsies, 35
different HPV sequences were identified. Seven were
completely characterized HPV types, 26 were designated
FA types (HPV sequences of about 430 nucleotides ampli-
fied with the FAP59 and FAP64 primers, either homologous
to previously described FA sequences or classified as
‘‘new’’ FA types), and one vs102-4 and one vs92.1 (Table
S1). HPV sequences within the B1 group were most
common, found in 89% (25 of 28) of the HPV positive
biopsies, followed by B2 sequences found in 18% (five of
28), and one type (HPV 27) from the A4 group in one sample
(patient 7) (Table S1). Multiple HPV sequences were found in
29% (eight of 28) of the HPV-positive biopsies.
Among the 44 HPV-positive swab samples from lesions,
51 different HPV sequences were identified. Nine were
completely characterized HPV types, 39 were designated
FA types and the two isolates vs102-4 and vs92.1 were also
detected (Table S1). HPV sequences within the B1 group
were found in 84% (37 of 44) of the HPV-positive swab
samples from lesions, followed by B2 types found in 41%
(18 of 44) (Table S1). Multiple HPV sequences were found in
57% (25 of 44) of the HPV-typed swab samples. No distinct
HPV type predominated, but HPV type 23 was detected in
five samples (three SCC and two AK) and HPV 5 in four
samples (Table S1).
Among the HPV-typed samples, nine new putative HPV
types, 14 new putative subtype, and five new putative
variants were identified (Table S2, on-line supplemental
material).
Detection of HPV particles in a swab sample To
investigate if the presence of viral DNA in swab samples
may be due to viral particles, a swab sample from
perilesional healthy skin of a patient with SCC (patient 20
in the reference Forslund et al, 2003) was analyzed by
electron microscopy. Viral particles of typical HPV morphol-
ogy were detected (Fig 1).
Effect of the stripping on the stratum corneum In order
to investigate the stripping effect on stratum corneum,
biopsies from non-stripped healthy skin and from the same
healthy skin after stripping were collected from one of the
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investigators. No difference in the thickness of the stratum
corneum could be observed by histopathological examina-
tion (Fig 2A and B). But on the adhesive surface of the tape
a dense layer of corneocytes were present (Fig 2C).
Discussion
This is a study aimed to investigate specifically whether the
HPV DNA prevalence on top of skin tumors differs from the
prevalence in biopsies from the same tumors. The pre-
valence of HPV DNA was indeed much higher (69%) in the
swab samples collected from lesions than in biopsies taken
after removal of superficial cell layers by repeated tape
stripping (12%). The result demonstrates that cutaneous
HPV DNA is commonly present on top of skin lesions but to
a lesser extent throughout the lesions. The fact that swab
samples from healthy skin sites were found to be HPV
positive to about the same extent as swab samples from
the top of tumors, suggests that presence of virus is not
specifically related to the tumor below. Whether the
presence of viral DNA in superficial skin is due to viral
Table I. Prevalence of HPV DNA in swab samples taken from the top of lesions and in biopsies (from the same lesions previously
stripped to remove superﬁcial layers), and in swab samples from healthy skin
Diagnosis Lesion swab Lesion biopsy Perilesion swab Forehead swab Buttock swab
Seborrheic keratosis 79% (34 of 43) 19% (eight of 43) 69% (30 of 43) 77% (33 of 43) 84% (36 of 43)
23% (10 of 43) 7% (three of 43) 37% (16 of 43) 32% (14 of 43) 30% (13 of 43)
Actinic keratosis 83% (38 of 46) 11% (five of 46) 89% (41 of 46) 89% (41 of 46) 69% (32 of 46)
41% (19 of 46) 2% (one of 46) 52% (24 of 46) 47% (22 of 46) 32% (15 of 46)
BCC 63% (69 of 109) 8% (nine of 109) 76% (83 of 109) 82% (90 of 109) 68% (74 of 109)
27% (29 of 109) 3% (three of 109) 38% (41 of 109) 49% (54 of 109) 31% (34 of 109)
SCC 58% (18 of 31) 19% (six of 31) 81% (25 of 31) 94% (29 of 31) 81% (25 of 31)
13% (four of 31) 6% (two of 31) 30% (nine of 31) 48% (15 of 31) 35% (11 of 31)
Totally 69% (159 of 229) 12% (28 of 229) 78% (179 of 229) 84% (193 of 229) 73% (167 of 229)
27% (62 of 229) 4% (nine of 229) 39% (90 of 229) 46% (105 of 229) 32% (73 of 229)
Italicised figures indicate prevalence of high copy numbers of amplicons (Xþ þ þ on gel).
HPV DNA, human papillomavirus DNA; BCC, basal cell carcinomas; SCC, squamous cell carcinoma.
Figure1
Human papillomavirus (HPV) particles from
perilesional healthy skin of an Australian
patient with squamous cell carcinoma. The
HPV particles were visualized by electron micro-
scopy from a sample collected with a cotton
swab. DNA from HPV types 23, 24, and 92 were
identified.
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particles or to episomal HPV genomes of infected cells is
not known. We could demonstrate viral particles in one
swab sample from perilesional skin of a patient with SCC,
suggesting that presence of viral particles is at least
contributing to the presence of HPV DNA in such samples.
In a previous study of Australian immunocompetent
patients with skin tumors, 71% (29 of 41) and 36% (15 of 41)
of paired perilesional swab samples and biopsies (collected
under standard surgical sterile conditions), respectively,
were found HPV positive by PCR (Forslund et al, 2003). The
proportion of samples with at least one HPV type in
common between paired biopsies and HPV-positive peri-
lesional swab samples was 38% (11 of 29). But in this study,
the corresponding proportion of at least one HPV type in
common between the stripped biopsies and HPV-positive
superficially collected samples from the same lesions was
only 8% (13 of 159).
Multiple HPV types were more commonly detected
among swab samples (57%) compared with that of biopsies
(31%) (p¼0.03). But since the determination of HPV types
was limited to analysis of only three clones from each
sample, it is possible that higher proportions of mixed
infections could have been demonstrated if more clones
had been analyzed.
The low prevalence of HPV in stripped biopsies suggests
that stripping is rather effective for removal of superficial
layers harboring HPV DNA from the lesions. The method of
tape stripping has previously been used in atopy patch tests
on non-lesional skin (Langeveld-Wildschut et al, 1995;
Tengvall Linder et al, 2000) and is expected to reduce the
superficial layers of the normal epidermis (predominantly
the stratum corneum). But we were not able to detect any
obvious effect of the tape stripping in histopathological
morphology after tape stripping of healthy epidermis. The
presence of a dense layer of corneocytes on the tape
indicates that the outermost loose part of stratum corneum
is removed by the stripping.
Overall, the HPV DNA prevalence on top of the tumors
(69%) was similar to that of swab samples from healthy
skin, taken at perilesional sites (78%), foreheads (84%), and
from the buttock (73%). It should be noted that the area for
collection of top of tumor samples was limited to the size of
the tumor (usually 1 and 2 cm in diameter) whereas a larger
area of about 5  5 cm was used for collection of superficial
swab samples from the healthy skin.
Among three swab samples from top of lesions, no HPV
DNA was detected although HPV DNA was found in the
stripped biopsies. Possibly, the larger amount of cells in
the biopsy may have resulted in improved ability to detect
the HPV DNA.
In the previous study of Australian skin tumor patients, a
relatively high HPV DNA prevalence was reported in AK by
the FAP-PCR method (60%, six of ten) (Forslund et al,
2003). This HPV DNA prevalence, is considerably higher
than the finding of 13% (six of 45) detected among the
stripped AK in this study (p¼ 0.004). Although population
differences cannot be excluded, it seems likely that the
approach of stripping the lesion before taking the biopsy
is the main reason for the reduced prevalence. Overall, the
HPV DNA prevalences of stripped punch biopsies in our
study are considerably lower than those found in other
studies using fresh biopsies, collected under standard
sterile conditions from immunocompetent patients, and
analyzed with various PCR protocols, e.g., among our
biopsies with the diagnosis of BCC, 8% (nine of 109)
demonstrated HPV DNA. The HPV DNA prevalences in BCC
in five other studies ranged from 21% to 55% (Shamanin
et al, 1996; Harwood et al, 2000; Meyer et al, 2000, 2001;
Wieland et al, 2000). For SCC, we detected HPV DNA in
19% (six of 31) of the biopsies compared with prevalences
between 27% and 54% in four other studies (Shamanin
et al, 1996; Harwood et al, 2000; Meyer et al, 2000, 2001).
Figure 2
Illustration of stratum corneum. (A) Non-stripped healthy skin, (B)
stripped healthy skin, and (C) corneocytes on tape after stripping.
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For AK, we observed an HPV DNA prevalence of 11% (five
of 46) compared with 36% (five of 14) by Meyer et al (2001),
and to 85% (46 of 54) by Pfister et al (2003). Except for the
differences in the sampling procedure (tape stripping), there
are also differences in the PCR methods used; however, the
FAP PCR method used in this study is established as having
high sensitivity for detection of HPV DNA on the skin of
almost all healthy adult individuals (Forslund et al, 1999;
Antonsson et al, 2000).
The fact that swab samples from the top of benign
lesions were somewhat more commonly HPV positive
(81%) than swab samples taken from the top of malignant
tumors (61%) may have several possible explanations, e.g.,
keratinization or morphological features resulting in an
increased tendency to trap environmental HPV. High
amounts of amplicons were detected among swab samples
from AK (42% had band intensity of Xþ þ þ ). This
suggests that a large amount of HPV DNA is present
superficially among these lesions. But the intensity of a PCR
band is dependent of the amplification efficiency of different
HPV genotypes with the general primers used and the
scored band intensities should not be regarded as absolute,
quantitative values. Furthermore, the variation of band
intensities between swab samples could also depend on
the amount of collected cells.
Interestingly, HPV DNA has been detected in 100% (11 of
11) of a benign neoplasm (Trichilemmomas) of the hair
follicle (Rohwedder et al, 1997). But in non-melanoma skin
cancer HPV DNA is reported to be lost after in vitro passage
(Purdie et al, 1993; Boxman et al, 2000a), suggesting that
the virus is not needed for maintenance of the malignant
phenotype or may even have been an environmental
contaminant of the specimen.
In conclusion, we have shown that cutaneous HPV DNA
is commonly present on the top of both skin lesions and
healthy skin, but is less common in the skin lesions
themselves. Consideration of the difference between viral
presence throughout the lesion and presence only on the
top of the lesions may be important in further studies aiming
to elucidate a putative role of HPV in non-melanoma skin
cancers.
Materials and Methods
Patients and sample collection Two hundred and twenty-nine
immunocompetent patients attending dermatology clinics in
Sweden (Stockholm, 107 patients; Gothenburg, 44 patients;
Malmo¨, 69 patients) and Austria (Vienna, nine patients) were,
following informed consent, providing swab and biopsy samples
for HPV DNA analysis. Subjects included were restricted to those
with the diagnoses of SCC, BCC, AK, and SK. The mean age was
74 y (range, 34–95 y), and 128 males and 101 women participated.
For collection of superficial cells, a cotton-tipped swab was
pre-wetted in saline (0.9% NaCl), rolled on the lesion (within
margins of the lesion), and suspended in 1 mL of saline.
From each patient, samples were also collected from healthy
perilesional skin, foreheads and buttock skin by cotton-tipped
swabs that were drawn to and fro 15 times within an area of 5  5
cm, and suspended in 1 mL of saline.
Before taking a biopsy sample, the skin was anesthetized
(without cleaning with ethanol) and stripped with tape (Art no 1527-1,
Transpore, 3M Health Care, St Paul Minnesota) that was attached
five times, then new tape was attached for another five times.
Thereafter, a 2 mm diameter punch biopsy was taken from the
tumor and the remaining tumor was excised and sent for
histopathological analysis as per normal procedures. AK and SK
were in most cases only diagnosed clinically. Samples were stored
at 201C and shipped frozen to the laboratory, except samples
from Gothenburg that were delivered unfrozen by overnight
express mail. The DNA from each punch biopsy was extracted
and dissolved in 200 mL TE buffer using a simple phenol-free
method (Forslund et al, 1999). For each swab sample, 5 mL of the
1 mL suspension was added directly to the PCR without DNA
extraction.
Consensus primer PCR The 25 mL PCR solution contained 5 mL
of the sample and 0.75 mM of each primer FAP59 and FAP64
(Forslund et al, 1999), 0.2 mM of each dNTP (Roche, Mannheim,
Germany), 0.2% BSA (Fraction V, Sigma, St. Louis, Missouri), 0.625
U AmpliTaq Gold DNA polymerase, GeneAmp 1  PCR buffer II
and 3.5 mM MgCl2 (Perkin-Elmer, Foster City, California). The PCR
was performed in a thermal cycler (Hybaid Omnigene, Middlesex,
UK), programmed for block temperature, using the parameters:
10 min at 941C followed by 45 cycles of 1.5 min at 941C, 1.5 min at
501C, and 1.5 min at 721C. In each test panel, H2O without DNA
was included as a negative control and 2000 copies of recombi-
nant HPV 5 genomes served as positive control. Five mL aliquots
of the PCR products were separated by electrophoresis in 2%
agarose gel (Type 1-A, Sigma-Aldrich, St Louis, Missouri) with
ethidium bromide (20 ng per mL, Sigma-Aldrich) in 1  TBE buf-
fer (Sambrook et al, 1989). The HPV-specific amplicons were
identified by size determination in ultraviolet light. The intensities of
the amplicons varied between samples and were therefore graded
arbitrarily from one to four (most intensive) in comparisons with the
positive control of HPV 5.
HPV typing Amplicons were cloned (three clones from each
sample were usually obtained) by the TOPO TA CloningKit
(Invitrogen, Leek, The Netherlands) and sequenced. Owing to
limited resources, not all amplicons were sequenced. All positive
‘‘pairs’’ of HPV-positive biopsies and swabs were sequenced. In
one case, the ‘‘positive pair’’ was not confirmed (the ‘‘positive’’
band was found to be human DNA in the sequencing). In addition,
the first 16 of the 45 swab samples from top of tumors that had
amplicons intensities of Xþ þ þ and the two first-collected
HPV-positive swab samples (oþ þ ) from top of tumors were
sequenced.
The nucleotide sequences were generated via cycle sequen-
cing (ABI Prism BigDye Terminator Cycle Sequencing, Applied
Biosystems, California) and an automated DNA sequencer (3730
DNA Sequencer, Applied Biosystems). The sequences were
compared with the GenBank database by the Blast program
(http://www.ncbi.nlm.nih.gov/BLAST/).
A new putative HPV type was designated FA and a consecutive
number, if the sequence showed o90% sequence homology with
any of previously known HPV sequences. FA isolates showing
sequence homology between 90% and o100% (90%–97%
homology¼ subtype, 98% and o100% homology¼ variant) to an
earlier identified FA isolate were given the same FA number plus an
extra succession number. Subtypes with a sequence homology
between greater than 90% and 97% to any completely character-
ized HPV type were also designated FA and a consecutive number.
Following sequence comparisons, the detected HPV types/
candidates were grouped according to phylogenetic classification
described by Chan et al (1995).
Quality control The quality/quantity of DNA of biopsy samples
and swab samples from lesions were analyzed in separate tubes
by using a PCR amplifying the human b-globin gene. The 25 mL
PCR solution contained 2.5 mL of the sample and 0.5 mM of each
primer for the human b-globin gene PC03 and PC05 (de Roda
Husman et al, 1995), 0.2 mM of each dNTP (Roche), 0.2% BSA
(Fraction V, Sigma), 0.625 U AmpliTaq Gold DNA polymerase,
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GeneAmp 1  PCR buffer II, and 3.5 mM MgCl2 (Perkin-Elmer).The
PCR was performed in a thermal cycler (Mastercycler, Eppendorf,
Hamburg, Germany), programmed for block temperature, using
the parameters: 10 min at 941C followed by 45 cycles of 1.5 min at
941C, 1.5 min at 451C, and 1.5 min at 721C. In each batch of tests,
H2O without DNA was included as a negative control. Five mL
aliquots from each PCR were then analyzed by PCR-EIA (Forslund
et al, 2002).
Statistical analysis The Fisher exact probability test was used to
compare subgroups with regard to the prevalences of HPV DNA.
p-values below 0.05 were regarded statistically significant.
The study adheres to the Declaration of Helsinki Guidelines and
was approved by the Ethics Committees of Karolinska Institute and
of Lund University, Sweden, and of Medical University of Vienna,
Austria.
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